These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1026 related items for PubMed ID: 15470215

  • 1. Lamivudine for patients with chronic hepatitis B and advanced liver disease.
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group.
    N Engl J Med; 2004 Oct 07; 351(15):1521-31. PubMed ID: 15470215
    [Abstract] [Full Text] [Related]

  • 2. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF.
    N Engl J Med; 1998 Jul 09; 339(2):61-8. PubMed ID: 9654535
    [Abstract] [Full Text] [Related]

  • 3. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA.
    N Engl J Med; 1999 Oct 21; 341(17):1256-63. PubMed ID: 10528035
    [Abstract] [Full Text] [Related]

  • 4. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.
    Antivir Ther; 2007 Oct 21; 12(8):1295-303. PubMed ID: 18240869
    [Abstract] [Full Text] [Related]

  • 5. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, BEHoLD AI463027 Study Group.
    N Engl J Med; 2006 Mar 09; 354(10):1011-20. PubMed ID: 16525138
    [Abstract] [Full Text] [Related]

  • 6. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group.
    N Engl J Med; 2006 Mar 09; 354(10):1001-10. PubMed ID: 16525137
    [Abstract] [Full Text] [Related]

  • 7. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK, Leung N, Shek WH, Zhang HY, Luk JM, Poon RT, Lo CM, Fan ST, Lau GK, Hong Kong Liver Fibrosis Study Group.
    J Clin Gastroenterol; 2008 Mar 09; 42(5):533-8. PubMed ID: 18344885
    [Abstract] [Full Text] [Related]

  • 8. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA, Bacon BR, Di Bisceglie AM.
    Liver Transpl; 2000 Nov 09; 6(6):715-20. PubMed ID: 11084057
    [Abstract] [Full Text] [Related]

  • 9. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.
    Hepatobiliary Pancreat Dis Int; 2004 May 09; 3(2):188-93. PubMed ID: 15138107
    [Abstract] [Full Text] [Related]

  • 10. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.
    Antivir Ther; 2005 May 09; 10(6):709-13. PubMed ID: 16218169
    [Abstract] [Full Text] [Related]

  • 11. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
    Wang L, Yan J, Zhang ZH, Wang JB, Du YZ, Li XY, Wang YZ.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct 09; 12(10):585-8. PubMed ID: 15504286
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H.
    J Gastroenterol Hepatol; 2007 Nov 09; 22(11):1929-35. PubMed ID: 17914972
    [Abstract] [Full Text] [Related]

  • 13. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug 09; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
    Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R.
    Am J Gastroenterol; 2008 Nov 09; 103(11):2776-83. PubMed ID: 18721244
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul 09; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.